EU, AstraZeneca and lung cancer
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed a feedback from the European Medicines Agency, the pharma company said Tuesday.
The Wall Street Journal on MSN8d
GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing PermissionIn one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
12d
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...
The biopharmaceutical company Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers seladelpar in combination with ...
Hosted on MSN18h
Most European Bourses Track Higher Midday of Muted Tuesday Trading, Ahead of Holiday BreakMost European bourses were ahead midday Tuesday, though trading activities were muted as global markets are set to remain closed on Wednesday for the holiday. In corporate news, AstraZeneca (AZN) ...
The Polish initiative establishes a proactive strategy for securing access to essential medicines and maintaining ...
AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung ...
Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback